Effect of vitamin D status on a disintegrin-like and metalloprotease with thrombospondin type 1 motif 13 (ADAMTS13) and interleukin 6 in patients with acute myeloid leukaemia.

Plain-language guide to PMID 40671161 (2025): phase 2 clinical trial of Vitamin D, K2, Magnesium and Zinc in 38 patients.

Key Facts

PMID: 40671161
Journal: European journal of medical research
Year: 2025
Study type: Clinical Trial, Phase II
Authors: Abdelhady DA et al. (4 authors)
DOI: 10.1186/s40001-025-02879-8
Registered trial: NCT05149339

What This Study Did, in Plain Language

What Was Tested

This phase 2 clinical trial looks at Vitamin D, K2, Magnesium and Zinc.

IL-6 produced by leukaemia cells suppresses ADAMTS13 activity and impairs hematopoietic differentiation.

This study investigated the impact of vitamin D supplementation on IL-6 and ADAMTS13 levels in patients newly diagnosed with AML.

Who Took Part

According to the abstract, 38 patients were involved.

By PubMed's age tags, the people studied were adults, middle-aged adults and older adults, both men and women.

A total of 38 newly diagnosed AML patients and 14 healthy individuals were included.

Among AML patients, 34 were found to have vitamin D deficiency.

How the Study Was Run

IL-6 and ADAMTS13 levels were measured in both groups at baseline.

Serum levels of IL-6, ADAMTS13 and vitamin D were measured on the 1st and 28th days of chemotherapy.

Statistical analyses included Mann-Whitney U test, Wilcoxon signed-rank test, and Spearman correlation.

What Was Measured

This study investigated the impact of vitamin D supplementation on IL-6 and ADAMTS13 levels in patients newly diagnosed with AML.

PubMed files the paper under topics including ADAMTS13 Protein, Case-Control Studies, Dietary Supplements, Interleukin-6, Leukemia, Myeloid, Acute, Vitamin D and Vitamin D Deficiency.

Author keywords: AML, Chemotherapy, IL-6 and Inflammation.

What This Means in Plain Language

This is a phase 2 clinical trial of Vitamin D, K2, Magnesium and Zinc in 38 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Its findings take up roughly 9 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2025 (European journal of medical research), a journal based in England.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.

Our Notes on the Compound

Vitamin D, K2, Magnesium and Zinc: Magnesium is described as required for AMPK to function.

Vitamin D, K2, Magnesium and Zinc in the library

Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.